Search

Displaying results 1211 - 1220 of 6831 in total
  1. Drug

    Calcium polycarbophil

    go.drugbank.com/drugs/DB14684
    Approved

    Less gas and bloating compared to psyllium laxative products, but can cause heartburn, and belly cramps. It is insoluble in water, dilute acids, and dilute alkali. … Polycarbophil is used to treat constipation. This drug may also be used to help relieve the symptoms of irritable bowel syndrome or diarrhea.

  2. Drug

    Elapegademase

    go.drugbank.com/drugs/DB14712
    Approved

    [F1937] Elapegademase is generated in _E. coli_, developed by Leadiant Biosciences and FDA approved on October 5, 2018.[L4654,F1939]

    Synonyms: -METHOXYPOLY(O, (74-SERINE (C>S),245-THREONINE (A>T))BOS TAURUS ADENOSINE DEAMINASE (BOVINE ADENOSINE AMINOHYDROLASE, EC=3.5.4.4)-(1-356)-PEPTIDE PRODUCED IN ESCHERICHIA COLI, AN AVERAGE OF 13 RESIDUES ARE SUBSTITUTED
  3. Drug

    Etafedrine

    go.drugbank.com/drugs/DB11587
    Approved

    This belongs to the family of medications called _decongestants_. It acts by narrowing blood vessels in the nasal passages, helping to relieve nasal congestion [F6]. … Ethylephedrine is be formed by alkylating ephedrine with ethyl iodide. The hydrochloride is be prepared by passing hydrogen chloride through a solution of ethylephedrine in diethyl ether [F6].

  4. Drug

    Obinutuzumab

    go.drugbank.com/drugs/DB08935
    ApprovedInvestigational

    [L54521] First approved by the FDA on February 26, 2016,[L54531] obinutuzumab is used to treat chronic lymphocytic leukemia, follicular lymphoma, and lupus nephritis.[L54521] … Obinutuzumab is a humanized anti-CD20 monoclonal antibody designed to treat B-cell malignancies.

  5. Drug

    Digoxin

    go.drugbank.com/drugs/DB00390
    ApprovedInvestigational

    [A178234] Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954. … They were one of the first to prescribe cardiac glycosides, according to ancient literature dating as early as the 1250s.[A178240]

  6. Drug

    Methotrexate

    go.drugbank.com/drugs/DB00563
    ApprovedInvestigational

    [A180322] Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast cancer and non-Hodgkin's lymphoma … [A180322] This inhibition leads to suppression of inflammation as well as prevention of cell division.

    Products: TEXATE-T
  7. Drug

    Amitriptyline

    go.drugbank.com/drugs/DB00321
    ApprovedInvestigational

    Amitriptyline is a tricyclic antidepressant that has been used to treat depression for decades. ELAVIL, a previously approved branded product of amitriptyline, was first approved by the FDA in 1961. … [A259342] Amitriptyline has been investigated in the treatment of pain-related conditions, attributed to its analgesic properties.[A174661]

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  8. Drug

    Dextropropoxyphene

    go.drugbank.com/drugs/DB00647
    ApprovedIllicitWithdrawn

    Dextropropoxyphene is an opioid analgesic manufactured by Eli Lilly and Company. It is used in the symptomatic treatment of mild pain. It displays antitussive and local anaesthetic actions. … Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the market in Europe and the United States.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  9. Drug

    Eltrombopag

    go.drugbank.com/drugs/DB06210
    ApprovedInvestigational

    Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked … Eltrombopag has also been recently approved (late 2012) for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based

  10. Drug

    Ribociclib

    go.drugbank.com/drugs/DB11730
    ApprovedInvestigational

    These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Ribociclib was approved by the FDA in March 2017 under the brand name Kisqali. … Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6).

    Mixtures: Kisqali Femara Co-pack, Kisqali Femara Co-pack